PRZOOM - /newswire/ -
Santa Clara, CA, United States, 2005/08/02 - MDM Group, Inc. (OTC.PK: MDDM) advises that the Company intends to proceed with the previously announced Collaboration Agreement with Sun Biomedical Laboratories.
MDM Group, Inc. (OTC.PK: MDDM) advises that the Company intends to proceed with the previously announced Collaboration Agreement with Sun Biomedical Laboratories, concentrating its business focus on the unique tests for illicit drugs that in the Company's opinion are positioned to become the industry standard, tests for clinical applications and also process and device technologies.
The Company further advises that it will not be proceeding with the Bamburgh Marrsh acquisition.
Oral fluid testing and/or diagnosis is rapidly being established as an extremely economic, efficient and non-invasive process that through the Company's technologies will be capable of delivering instant on the spot results as opposed to the far more expensive, invasive and delayed results of tests using urine or blood samples. As referenced within an Interview published by the Wall Street Journal last April 19: "A sample of saliva can have within it DNA, RNA, proteins, germs, viruses, fatty acids and a host of interesting molecules useful in disease detection...whatever is in the blood is probably also in saliva. It is, in most of the case, a reflection of our blood, it's a blood filtrate."
MDM Group's business interests are focused on the Security, Biodefense and Homeland Security industries.
Safe Harbor Statement
The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.
Source: MDM Group, Inc.